In last trading session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw 0.48 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $4.14 trading at $0.04 or 0.98% at ring of the bell on the day assigns it a market valuation of $636.57M. That closing price of MREO’s stock is at a discount of -21.26% from its 52-week high price of $5.02 and is indicating a premium of 74.15% from its 52-week low price of $1.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.99 million shares which gives us an average trading volume of 910.73K if we extend that period to 3-months.
For Mereo Biopharma Group Plc ADR (MREO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.02 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Upright in the green during last session for gaining 0.98%, in the last five days MREO remained trading in the red while hitting it’s week-highest on Monday, 09/23/24 when the stock touched $4.14 price level, adding 2.36% to its value on the day. Mereo Biopharma Group Plc ADR’s shares saw a change of 79.22% in year-to-date performance and have moved -2.59% in past 5-day. Mereo Biopharma Group Plc ADR (NASDAQ:MREO) showed a performance of -11.35% in past 30-days. Number of shares sold short was 4.54 million shares which calculate 5.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7.5 to the stock, which implies a rise of 44.8% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would jump 3.38% in reaching the projected high whereas dropping to the targeted low would mean a gain of 3.38% for stock’s current value.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
This year revenue growth is estimated to rise 43.60% from the last financial year’s standing.
And 5 analysts are in estimates of company making revenue of 14.64M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 41.78% during past 5 years.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Insiders are in possession of 1.08% of company’s total shares while institution are holding 65.49 percent of that, with stock having share float percentage of 66.20%. Investors also watch the number of corporate investors in a company very closely, which is 65.49% institutions for Mereo Biopharma Group Plc ADR that are currently holding shares of the company. RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at MREO for having 15.31 million shares of worth $55.11 million. And as of 2024-06-30, it was holding 2.1859 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6838 of outstanding shares, having a total worth of $42.45 million.
